Page last updated: 2024-09-05

lapatinib and Thyroid Neoplasms

lapatinib has been researched along with Thyroid Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, L; Cheng, L; Jin, Y; Liu, M; Ruan, M	1

Other Studies

1 other study(ies) available for lapatinib and Thyroid Neoplasms

Article	Year
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E. Oncotarget, 2017, Mar-21, Volume: 8, Issue:12 Topics: Benzimidazoles; Blotting, Western; Carcinoma, Papillary; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Imidazoles; Inhibitory Concentration 50; Lapatinib; MAP Kinase Kinase 1; Microscopy, Fluorescence; Mutation, Missense; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms	2017

Article

Year

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.

Oncotarget, 2017, Mar-21, Volume: 8, Issue:12

Topics: Benzimidazoles; Blotting, Western; Carcinoma, Papillary; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Imidazoles; Inhibitory Concentration 50; Lapatinib; MAP Kinase Kinase 1; Microscopy, Fluorescence; Mutation, Missense; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms

2017